Patent intelligence · US
US 9867785
Methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells
Methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells
Patent details — US 9867785
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 16, 2018
- Expiration
- Jan 11, 2038
- Applicant
- EnGeneIC Molecular Delivery Pty Ltd
- Claims
- 12
- CPC classes
- A61K, A61K31/704, A61K47/6879, A61K47/6901
Quick answer
US 9867785 (Methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells) is held by EnGeneIC Molecular Delivery Pty Ltd. Status: granted. Granted Jan 16, 2018. Expires Jan 11, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- EnGeneIC Molecular Delivery Pty Ltd
- Grant date
- Expiration
- Claims
- 12
- CPC classes
- A61K, A61K31/704, A61K47/6879, A61K47/6901, A61K9/5068, A61P
More from EnGeneIC Molecular Delivery Pty Ltd
Related pharmaceutical patents in our USPTO index.
-
US 12421273
Ectonucleotidase inhibitors and methods of use thereof
granted -
US 12414968
Compositions comprising bacterially derived minicells and methods of using the same
granted -
US 12357687
Compositions and vaccines for treating and/or preventing viral infections, and methods of using the same
granted -
US 12337033
Encapsulated glycolipid antigens for treatment of neoplastic diseases
granted -
US 12076418
Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo
granted -
US 11964021
Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors
granted -
US 11883433
Chimeric antigen receptor comprising anti-mesothelin scFv, and use thereof
granted -
US 11858957
Ectonucleotidase inhibitors and methods of use thereof
granted
Frequently asked questions
What is US patent 9867785?
US 9867785 (Methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells) is held by EnGeneIC Molecular Delivery Pty Ltd. Status: granted. Granted Jan 16, 2018. Expires Jan 11, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9867785?
EnGeneIC Molecular Delivery Pty Ltd is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 53 pharmaceutical patents for this assignee.
When does US 9867785 expire?
Our index shows an expiration date of Jan 11, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.